Published online before print January 24, 2002, doi: 10.1161/hh0402.105668
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 20, 2001
Revised on January 14, 2002
Accepted on January 14, 2002
Lovastatin Enhances Ecto-5'-Nucleotidase Activity and Cell Surface Expression in Endothelial Cells. Implication of Rho-Family GTPases
S. Ledoux *;
From INSERM U426 (S.L., D.L., M.E., I.R., G.F.), Faculté de Médecine Xavier Bichat, Université Paris 7; INSERM U538 (G.T.), Faculté de Médecine Saint-Antoine; and INSERM U460 (J.B.M.), Faculté de Médecine Xavier Bichat, Université Paris 7, Paris, France.
* To whom correspondence should be addressed. E-mail: ledoux{at}bichat.inserm.fr.
Extracellular adenosine production by the GPI-anchored Ecto-5'-Nucleotidase (Ecto-5'-Nu) plays an important role in the cardiovascular system, notably in defense against hypoxia. It has been previously suggested that HMG-CoA reductase inhibitors (HRIs) could potentiate the hypoxic stimulation of Ecto-5'Nu in myocardial ischemia. In order to elucidate the mechanism of Ecto-5'-Nu stimulation by HRIs, Ecto-5'-Nu activity and expression were determined in an aortic endothelial cell line (SVAREC) incubated with lovastatin. Lovastatin enhanced Ecto-5'-Nu activity in a dose-dependent manner. This increase was not supported by de novo synthesis of the enzyme because neither the mRNA content nor the total amount of the protein were modified by lovastatin. By contrast, lovastatin enhanced cell surface expression of Ecto-5'-Nu and decreased endocytosis of Ecto-5'-Nu, as evidenced by immunostaining. This effect appeared unrelated to modifications of cholesterol content or Ecto-5'-Nu association with detergent-resistant membranes. The effect of lovastatin was reversed by mevalonate, the substrate of HMG-CoA reductase, by its isoprenoid derivative, geranyl-geranyl pyrophosphate, and by cytotoxic necrotizing factor, an activator of Rho-GTPases. Stimulation of Ecto-5'-Nu by lovastatin enhanced the inhibition of platelet aggregation induced by endothelial cells. In conclusion, lovastatin enhances Ecto-5'-Nu activity and membrane expression in endothelial cells. This effect seems independent of lowering cholesterol content but could be supported by an inhibition of Ecto-5'-Nu endocytosis through a decrease of Rho-GTPases isoprenylation.
Key words: HMG-CoA reductase inhibitors • Ecto-5'-Nucleotidase • isoprenoids • Rho-GTPases • endocytosis
This article has been cited by other articles:
 |
|
 |
|
  P. Meijer, W. J.G. Oyen, D. Dekker, P. H.H. van den Broek, C. W. Wouters, O. C. Boerman, G. J. Scheffer, P. Smits, and G. A. Rongen Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo: A New Perspective on Cardiovascular Protection Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 963 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jalkanen and M. Salmi VAP-1 and CD73, Endothelial Cell Surface Enzymes in Leukocyte Extravasation Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 18 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Merla, Y. Ye, Y. Lin, S. Manickavasagam, M.-H. Huang, R. J. Perez-Polo, B. F. Uretsky, and Y. Birnbaum The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1918 - H1928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sanada, H. Asanuma, T. Minamino, K. Node, S. Takashima, H. Okuda, Y. Shinozaki, A. Ogai, M. Fujita, A. Hirata, et al. Optimal Windows of Statin Use for Immediate Infarct Limitation: 5'-Nucleotidase as Another Downstream Molecule of Phosphatidylinositol 3-Kinase Circulation, October 12, 2004; 110(15): 2143 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sanada, H. Asanuma, O. Tsukamoto, T. Minamino, K. Node, S. Takashima, T. Fukushima, A. Ogai, Y. Shinozaki, M. Fujita, et al. Protein Kinase A as Another Mediator of Ischemic Preconditioning Independent of Protein Kinase C Circulation, July 6, 2004; 110(1): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Galinanes and A. G Fowler Role of clinical pathologies in myocardial injury following ischaemia and reperfusion Cardiovasc Res, February 15, 2004; 61(3): 512 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ledoux, R. Yang, G. Friedlander, and D. Laouari Glucose Depletion Enhances P-Glycoprotein Expression in Hepatoma Cells: Role of Endoplasmic Reticulum Stress Response Cancer Res., November 1, 2003; 63(21): 7284 - 7290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zaugg, E. Lucchinetti, C. Garcia, T. Pasch, D. R. Spahn, and M. C. Schaub Anaesthetics and cardiac preconditioning. Part II. Clinical implications Br. J. Anaesth., October 1, 2003; 91(4): 566 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhatnagar Surviving Hypoxia: The Importance of Rafts, Anchors, and Fluidity Circ. Res., May 2, 2003; 92(8): 821 - 823. [Full Text] [PDF]
|
|
|
|
|
|
S. Ledoux, I. Runembert, K. Koumanov, J.B. Michel, G. Trugnan, and G. Friedlander Hypoxia Enhances Ecto-5'-Nucleotidase Activity and Cell Surface Expression in Endothelial Cells: Role of Membrane Lipids Circ. Res., May 2, 2003; 92(8): 848 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Pierini, R. J. Eddy, M. Fuortes, S. Seveau, C. Casulo, and F. R. Maxfield Membrane Lipid Organization Is Critical for Human Neutrophil Polarization J. Biol. Chem., March 14, 2003; 278(12): 10831 - 10841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Mason, Z. Ahmed, R. Mankoff, E. A. Lidington, S. Ahmad, V. Bhatia, A. Kinderlerer, A. M. Randi, and D. O. Haskard Statin-Induced Expression of Decay-Accelerating Factor Protects Vascular Endothelium Against Complement-Mediated Injury Circ. Res., October 18, 2002; 91(8): 696 - 703. [Abstract] [Full Text] [PDF]
|
|